Observed Signal · Oct 27, 2026 · Funding · Source: Tech.eu (European Tech & Deals) · Impact: 3/5 · Sentiment: Positive
Atlas Bio Raises $12.5M for AI Clinical Trial Simulations
Swiss biotech startup Atlas Bio emerged from stealth with a total of $12.5 million in funding to develop an AI foundation model for in-silico clinical trials. The Seed round of $10 million was led by Creandum, with participation from First Momentum Ventures and LEA Partners, who also led a previously undisclosed pre-Seed round of $2.5 million. The company's model, trained on 2 million human RNA readouts, simulates patient-level drug efficacy and safety, aiming to replace Phase II trials and animal testing. Atlas Bio is already working with a top-10 global pharma company and a Basel-based biotech client that has eliminated animal testing in a specific workflow. The founders, Simon Romanski and Sebastian Bayer, emphasize the potential to reduce drug development costs and timelines significantly.
High relevance for the biotech and pharma industry, showcasing AI's potential to transform clinical trials and reduce reliance on animal testing. This funding signals growing investor interest in AI-driven drug development, with implications for cost and time efficiency in the sector.
Track Creandum Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- Atlas Bio raised a $10M Seed round led by Creandum, plus a $2.5M pre-Seed round led by First Momentum Ventures and LEA Partners, totaling $12.5M.
- The company's AI model is trained on roughly 2 million RNA readouts from human tissue.
- Atlas Bio is working with a top 10 global pharma company and a Basel-based biotech client that has eliminated animal testing in a specific workflow.
- The funding will be used to scale scientific and commercial teams and onboard further enterprise clients through 2026.
Connected Companies & Entities
1 Entity mapped“Creandum led the round, with Partner Katharina Wilhelm joining the board.”
Ontology Mapping & Concepts
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Biolevate raises €30M Series A for life sciences AI
Biolevate, a Paris-based life sciences AI company, has raised €30 million in Series A funding to scale its enterprise agentic AI platform designed to automate scientific and regulatory workflows. The round was co-led by RAISE France and Orange Ventures, with participation from MSD Global Health Innovation Fund, Station F, and existing investor EQT Ventures. The platform enables life sciences organizations to run thousands of concurrent AI agents, with outputs grounded in source evidence and human oversight, facilitating use in regulated environments. Since its 2024 seed round, Biolevate has expanded to over a dozen enterprise customers, achieving significant efficiency gains in literature reviews and regulatory intelligence. The company is opening a US office in Boston, has doubled headcount, and plans to double again, while also filing patents in Europe.
bit.bio Raises $25M Series D for Cell Models
bit.bio, a human cell programming company, announced it has closed a $25 million Series D funding round. The investment will be used to expand its portfolio of human cell models and increase access to its technology for pharmaceutical, biotechnology, and research organizations. The round includes participation from existing investor M&G Investments and Dr Jonathan Milner, founder and former CEO of Abcam. The company's opti-ox™ platform enables the production of defined human cell types at scale, and its ioCells portfolio includes over 50 cell types for drug discovery and disease research. The funding comes as AI accelerates drug candidate identification and there is growing demand for alternatives to animal testing.
Cori Clinical Raises €3.8M to Accelerate Clinical Trials
London-based Cori Clinical, a startup providing an AI-powered intelligence layer for clinical trials, has raised €3.8 million in a Seed round led by Breega, with participation from Enzo, Heartfelt, Together Ventures, and Bynd. The company plans to use the funds to expand delivery capacity, grow its team, and deepen regulatory and clinical intelligence in its platform. Dr. Emma Ogburn joins as Chief Clinical Officer from Lindus Health. Founded in 2025 by Jorn Jansen Schoonhoven (CEO) and Patricio Fernández (CTO), Cori Clinical creates a 'living blueprint' for trials, integrating internal knowledge with external data from registries and regulatory bodies like FDA, MHRA, and EMA. The startup claims its approach could reduce average trial set-up costs by at least 33%. It already works with two of the top five global CROs and has customers like Erasmus MC.
Receive all future signals for Creandum & competitors in your briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.